Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Envafolimab - Alphamab Oncology/Ascletis/3D Medicine

X
Drug Profile

Envafolimab - Alphamab Oncology/Ascletis/3D Medicine

Alternative Names: ASC 22; ENWEIDA; KN-035

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab Oncology
  • Developer 3D Medicines; Alphamab Oncology; Ascletis; Chipscreen Biosciences; Jiangsu Simcere Pharmaceutical; Sun Yat-Sen University; The First Affiliated Hospital of Xiamen University; TRACON Pharmaceuticals
  • Class Antibodies; Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Solid tumours
  • Phase III Biliary cancer; Non-small cell lung cancer
  • Phase II Endometrial cancer; Gastrointestinal cancer; Hepatitis B; HER2 positive breast cancer; HIV infections; Liver cancer; Malignant fibrous histiocytoma; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 03 Apr 2024 Efficacy data from a phase II ENVASARC trial for Malignant fibrous histiocytoma and Soft tissue sarcoma released by TRACON Pharmaceuticals
  • 13 Mar 2024 Jiangsu Simcere Pharmaceutical terminated a phase II trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (SC), due to the sponsor's research and development strategy adjustment (NCT05148195)
  • 06 Feb 2024 CTP push: 700368762: Updated KDM, added devline as qualifier was different than previous devlines
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top